Access cutting-edge bladder cancer treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.
Access bladder cancer specialists in Cleveland at no cost
This study follows strict safety protocols and ethical guidelines
All study-related bladder cancer treatment provided free
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C),
Sponsor: BicycleTx Limited
Check if you qualify for this bladder cancer clinical trial in Cleveland, OH
If you're searching for bladder cancer treatment options in Cleveland, OH, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced bladder cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.